Antiangiogenic therapy and tumor progression

Cancer Cell

Volumn 5, Issue 1, 2004, Pages 13-17

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BCR ABL PROTEIN; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; OXYGEN; PROTEIN INHIBITOR; RADIOACTIVE IODINE; SURVIVIN; THROMBOSPONDIN 1; TIRAPAZAMINE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIBIOTIC RESISTANCE; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CELL ACTIVATION; CELL AGING; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; HYPOXIA; LEUKEMIA; METASTASIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; TRANSACTIVATION; TUMOR VASCULARIZATION;

EID: 1642472018     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00336-2     Document Type: Review

References (68)

1. Adelman D.M., Maltepe E., Simon M.C. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev. 13:1999;2478-2483.
2. Adelman D.M., Gertsenstein M., Nagy A., Simon M.C., Maltepe E. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev. 14:2000;3191-3203.
3. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., Niizeki H., Kawamura K., Hosokawa M., Asaka M. Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61:2001;6548-6554.
4. Ameri, K., Lewis, C.E., Raida, M., Sowter, H., Hai, T., and Harris, A.L. (2003). Anoxic induction of ATF-4 via HIF-1 independent pathways of protein stabilization in human cancer cells. Blood. Published online November 20, 2003. 10.1182/blood-2003-06-1859.
5. Blagosklonny M.V. Hypoxia-inducible factor. Achilles' heel of antiangiogenic cancer therapy Int. J. Oncol. 19:2001;257-262.
6. Blagosklonny M.V. Oncogenic resistance to growth-limiting conditions. Nat. Rev. Cancer. 2:2002;221-225.
7. Brusselmans K., Bono F., Maxwell P., Dor Y., Dewerchin M., Collen D., Herbert J.M., Carmeliet P. HIF-2α) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J. Biol. Chem. 276:2001;39192-39196.
8. Bottaro D.P., Liotta L.A. Cancer. Out of air is not out of action Nature. 423:2003;593-595.
9. Brown J.M., Giaccia A.J. The unique physiology of solid tumors. Opportunities (and problems) for cancer therapy Cancer Res. 58:1998;1408-1416.
10. Cairns R.A., Kalliomaki T., Hill R.P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61:2001;8903-8908.
11. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P.et al. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
12. Dachs G.U., Patterson A.V., Firth J.D., Ratcliffe P.J., Townsend K.M., Stratford I.J., Harris A.L. Targeting gene expression to hypoxic tumor cells. Nat. Med. 3:1997;515-520.
13. de Candia P., Solit D.B., Giri D., Brogi E., Siegel P.M., Olshen A.B., Muller W.J., Rosen N., Benezra R. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc. Natl. Acad. Sci. USA. 100:2003;12337-12342.
14. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 1:2002;31-36.
15. Folkman J. Tumor angiogenesis. therapeutic implications N. Engl. J. Med. 285:1971;1182-1186.
16. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 13:2003;159-167.
17. Garayoa M., Martinez A., Lee S., Pio R., An W.G., Neckers L., Trepel J., Montuenga L.M., Ryan H., Johnson R.et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation. a possible promotion mechanism of carcinogenesis Mol. Endocrinol. 14:2000;848-862.
18. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2:2003;803-811.
19. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., Johnson R.S. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23:2003;359-369.
20. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
21. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
22. Hansen-Algenstaedt N., Stoll B.R., Padera T.P., Dolmans D.E., Hicklin D.J., Fukumura D., Jain R.K. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60:2000;4556-4560.
23. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47.
24. Hockel M., Vaupel P. Tumor hypoxia. definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 93:2001;266-276.
25. Hockel M., Schlenger K., Hockel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59:1999;4525-4528.
26. Huang J., Frischer J.S., Serur A., Kadenhe A., Yokoi A., McCrudden K.W., New T., O'Toole K., Zabski S., Rudge J.S.et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. USA. 100:2003;7785-7790.
27. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. Jr. HIFα targeted for VHL-mediated destruction by proline hydroxylation. Implications for O2 sensing Science. 292:2001;464-468.
28. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A.V., Hebestreit H.F., Mukherji M., Schofield C.J.et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
29. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy. A new paradigm for combination therapy Nat. Med. 7:2001;987-989.
30. Jiang B.H., Semenza G.L., Bauer C., Marti H.H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 271:1996;C1172-C1180.
31. Kaelin W.G. Jr. How oxygen makes its presence felt. Genes Dev. 16:2002;1441-1445.
32. Kerbel R.S. A cancer therapy resistant to resistance. Nature. 390:1997;335-336.
33. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739.
34. Kieran M.W., Folkman J., Heymach J. Angiogenesis inhibitors and hypoxia. Nat. Med. 9:2003;1104-1105.
35. Kim C.Y., Tsai M.H., Osmanian C., Graeber T.G., Lee J.E., Giffard R.G., DiPaolo J.A., Peehl D.M., Giaccia A.J. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen condition. Cancer Res. 57:1997;4200-4204.
36. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24.
37. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., Hicklin D., Kerbel R.S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8:2002;221-232.
38. Knowles H.J., Raval R.R., Harris A.L., Ratcliffe P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63:2003;1764-1768.
39. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., Iyer N., LaRusch J., Pak B., Taghavi P., Semenza G.L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63:2003;1138-1143.
40. Laderoute K.R., Alarcon R.M., Brody M.D., Calaoagan J.M., Chen E.Y., Knapp A.M., Yun Z., Denko N.C., Giaccia A.J. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6:2000;2941-2950.
41. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:2002;2478-2482.
42. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 3:2003;363-375.
43. Pan Q., Bao L.W., Kleer C.G., Brewer G.J., Merajver S.D. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol. Cancer Ther. 2:2003;617-622.
44. Parrinello S., Samper E., Krtolica A., Goldstein J., Melov S., Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 5:2003;741-747.
45. Pelikan D.M., Lion H.L., Hermans J., Goslings B.M. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin. Endocrinol. 47:1997;713-720.
46. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3:2003;347-361.
47. Peters K.B., Brown J.M. Tirapazamine. A hypoxia-activated topoisomerase II poison Cancer Res. 62:2002;5248-5253.
48. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62:2002;4316-4324.
49. Reese D.M. Choice of hormonal therapy for prostate cancer. Lancet. 355:2000;1474-1475.
50. Rofstad E.K., Rasmussen H., Galappathi K., Mathiesen B., Nilsen K., Graff B.A. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62:2002;1847-1853.
51. Ryan H.E., Lo J., Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
52. Safran M., Kaelin W.G. Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111:2003;779-783.
53. Salnikow K., Costa M., Figg W.D., Blagosklonny M.V. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res. 60:2000;5630-5634.
54. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 1:2002;13-15.
55. Schipani E., Ryan H.E., Didrickson S., Kobayashi T., Knight M., Johnson R.S. Hypoxia in cartilage. HIF-1α is essential for chondrocyte growth arrest and survival Genes Dev. 15:2001;2865-2876.
56. Semenza G.L. Surviving ischemia. Adaptive responses mediated by hypoxia-inducible factor 1 J. Clin. Invest. 106:2000;809-812.
57. Semenza G.L. HIF-1 and tumor progression. Pathophysiology and therapeutics Trends Mol. Med. 8:2002;S62-S67.
58. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:2003;721-732.
59. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12:1992;5447-5454.
60. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:2001;6669-6673.
61. Stackpole C.W., Groszek L., Kalbag S.S. Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J. Natl. Cancer Inst. 86:1994;361-367.
62. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 425:2003;307-311.
63. Steeg P.S. Angiogenesis inhibitors. motivators of metastasis? Nat. Med. 9:2003;822-823.
64. Sutphin P.D., Chan D.A., Giaccia A.J. Dead cells don't form tumors. HIF-dependent cytotoxins Cell Cycle. 3:2004;160-163.
65. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA. 99:2002;4349-4354.
66. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528.
67. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors. Association with angiogenesis, invasion, and progression Cancer. 88:2000;2606-2618.
68. Zietman A.L., Dallow K.C., McManus P.A., Heney N.M., Shipley W.U. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology. 47:1996;236-239.